Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .
Efficacy and tolerability of the lipidosterolic extract of Serenoa repens (Permixon) in benign prostatic hyperplasia: a double-blind comparison of two dosage regimens.
This 3-month double-blind , r and omized , parallel-group study compared the efficacy and tolerability of two regimens of the lipido-sterolic extract of Serenoa repens ( Permixon ) ( two 160-mg capsules once daily [ OD ] and one 160-mg capsule twice daily [ BID ] ) in 100 out patients with symptomatic benign prostatic hyperplasia ( BPH ) . Both regimens significantly ( P < .0001 ) reduced the International Prostate Symptom Score ( I-PSS ) mean total score from baseline ; improvements achieved statistical significance after the first month and were maintained for the duration of the study . Significant ( P < .05 ) and rapid improvements from baseline to the end of month 1 also occurred in I-PSS quality -of-life ( QoL ) scores , maximum and mean urinary flow rates , and residual urine volume ; this benefit was further increased at month 3 for I-PSS total score and QoL and residual volume , and was maintained for maximum and mean flow rates . A highly significant decrease ( P < .001 ) in residual urine was observed in both groups . No significant differences were noted between regimens . Clinical adverse events occurred at a similar incidence in both groups ( BID , 24 % ; OD , 22 % ) and were deemed unrelated or unlikely to be related to Permixon
Serenoa repens was not more effective than placebo for treatment of urinary symptoms consistent with BPH
BACKGROUND Benign prostatic hyperplasia ( BPH ) , a nonmalignant enlargement of the prostate , can lead to obstructive and irritative lower urinary tract symptoms ( LUTS ) .
The pharmacologic use of plants and herbs ( phytotherapy ) for the treatment of LUTS associated with BPH is common .
The extract of the berry of the American saw palmetto , or dwarf palm plant , Serenoa repens ( also known by its botanical name of Sabal serrulatum ) , is one of several phytotherapeutic agents available for the treatment of BPH .
OBJECTIVES This systematic review aim ed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH .